Literature DB >> 32227535

Patient length of stay, patient readmission rates and the provision of professional interpreting services in healthcare in Australia.

Jonathan Beagley1, Jim Hlavac1, Emiliano Zucchi1,2.   

Abstract

Linguistic and ethnic diversity is a feature of patient profiles at almost all public healthcare facilities in urban areas in Australia. Patients with limited proficiency in the socially dominant language - in this case Limited English proficiency (LEP) patients - commonly form a significant patient group in public healthcare settings. Communication barriers that exist between patients and healthcare professionals necessitate the provision of translation and interpreting (T&I) services. This study presents longitudinal data from Melbourne, Australia, on the provision of (T&I) services together with patient length of stay (LOS) and patient readmission rates over a 10-year period at a large, public healthcare provider. Patient LOS and patient readmission rates are key metrics for effective diagnosis and treatment of patients and commonly used to measure the performance of various aspects of healthcare provision. The augmentation of T&I services within a general policy of patient-centred care is shown to accompany decreased LOS and lower readmission rates for LEP patients.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  medical interpreting; patient length of stay; patients with limited English proficiency; professional interpreting services; readmission rates

Mesh:

Year:  2020        PMID: 32227535     DOI: 10.1111/hsc.12989

Source DB:  PubMed          Journal:  Health Soc Care Community        ISSN: 0966-0410


  1 in total

1.  Testing the use of translation apps to overcome everyday healthcare communication in Australian aged-care hospital wards-An exploratory study.

Authors:  Kerry Hwang; Sue Williams; Emiliano Zucchi; Terence W H Chong; Monita Mascitti-Meuter; Dina LoGiudice; Anita M Y Goh; Anita Panayiotou; Frances Batchelor
Journal:  Nurs Open       Date:  2021-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.